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Abstract
Background—In preparation for a randomized controlled trial (RCT), we conducted a pilot RCT 
of the acceptability and feasibility of diaphragms and candidate vaginal microbicide for sexually 
transmitted infection prevention among high-risk women in Madagascar.
Methods—Participants were randomized to four arms: (1) diaphragm (worn continuously) with 
Acidform™ applied in the dome; (2) diaphragm (worn continuously) with placebo gel 
hydroxyethylcellulose (HEC) in the dome; (3) HEC applied intravaginally before sex; (4) 
Acidform applied intravaginally before sex. All women were given condoms. Participants were 
followed weekly for 4 weeks. We fit unadjusted negative binomial regression models with robust 
variance estimators to generate the proportion of sex acts with casual partners where condoms and 
experimental study products were used.
Results—Retention was 98% among 192 participants. Experimental product use with casual 
partners was high, reported in 85%, 91%, 74%, and 81% of sex acts for women in the Acidform-
diaphragm, HEC-diaphragm, HEC-alone, and Acidform-alone arms, respectively. However, the 
proportion reporting product use during 100% of acts with casual partners over the full follow-up 
period was much lower: 28% to 29% in the gel-diaphragm arms and 6% to 10% in gel-alone arms. 
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Women used condoms in 62% to 67% of sex acts with casual partners, depending on the 
randomization arm. Participants found diaphragms easy to insert (97%) and remove (96%). 
Acidform users (with or without the diaphragm) reported more genitourinary symptoms than HEC 
users (14% vs. 5% of visits).
Conclusions—A sexually transmitted infection prevention RCT of candidate microbicide with 
and without the diaphragm appears acceptable and feasible in this population.
Women in resource-poor settings suffer disproportionately from sexually transmitted 
infections (STIs).1,2 Madagascar is a low-income country where STIs constitute a major 
public health concern, and rates are particularly high among women who exchange sex for 
money or goods. In 2001, among asymptomatic sex workers, 74% to 78% were infected 
with Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), trichomoniasis, or syphilis.3 
In a separate 2001 trial of male and female condom promotion among 1000 female sex 
workers, 6 months after receiving presumptive treatment, the combined prevalence of 
GC/CT infection was 26%.4 The high STI prevalence indicates that better control efforts are 
needed, especially given that STIs are likely to increase risk of HIV acquisition.5–7 HIV 
rates in Madagascar are currently low: the estimated prevalence in 2006 was <2% in 
vulnerable groups and 0.95% in the general population.8
Although male condoms, when used correctly and consistently, are the most effective 
method currently available for prevention of most STIs,9 many women lack the social and 
economic power to insist that their sex partners use them.2 Therefore, additional prevention 
methods are needed that are appropriate for and accessible to women.10,11 The diaphragm, 
used worldwide for prevention of pregnancy, has received attention as a possible infection-
prevention method.12–14 Because GC, CT, and probably HIV preferentially infect the cervix 
and upper genital tract in women,15 physical barriers, such as diaphragms, may prevent 
sexually transmitted pathogens from reaching the cervix and thereby reduce infection risk. 
Several observational studies report protective effects for diaphragms against STIs and their 
long-term sequelae,16–21 though a recent large-scale randomized controlled trial (RCT) of 
women in Zimbabwe and South Africa [Methods for Improving Reproductive Health in 
Africa (MIRA)] found no added protective benefit of a diaphragm with commercial 
lubricant (compared with male condoms only) for HIV or STI prevention.22,23 Topical 
vaginal microbicides have also been promoted as female-initiated methods to prevent 
STI/HIV acquisition, although no effective product is yet available.24 Several studies have 
reported high acceptability of microbicides and diaphragms for STI prevention among both 
women and men.25–31
We plan to conduct an RCT evaluating the STI-prevention effectiveness of 2 women-
initiated methods—candidate vaginal microbicide and latex diaphragm—individually and in 
combination. In anticipation of the RCT, we carried out this 4-arm, partially masked, 
randomized, prospective pilot trial to assess the acceptability of assigned study products 
(diaphragm, candidate microbicide and placebo gels, gel applicators, and male condoms) 
and the feasibility of conducting a large clinical trial measuring their effectiveness for GC 
and CT prevention. Over 4 weeks, we measured participants’ use of and comfort with study 
products.
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Study Sites and Population
Participants were recruited through community outreach in 4 cities in Madagascar: 
Antananarivo, Antsiranana, Mahajanga, and Toamasina. Eligible women were 15 to 55 years 
old (though the youngest participant was 16 years old), had at least 4 sex partners in the past 
month, reported less than 100% condom use in the past 2 weeks, intended to stay in the area 
for the next month, were not pregnant or planning pregnancy in the next 2 months, had no 
allergy to latex and no physical abnormality that precluded diaphragm use, and were able to 
give informed consent.
Study Products
Participants used various combinations (see below) of 6 study products: candidate topical 
microbicide Acidform™ (Instead, LA Jolla, CA); placebo gel, hydroxyethylcellulose (HEC) 
(ReProtect LLC, Baltimore, MD); latex diaphragm (All-Flex Arcing Spring Diaphragm, 
Ortho-McNeil Pharmaceutical, Titusville, NJ); disposable, paper gel applicator (TekPak, 
Marion, AL); reusable, plastic gel applicator (Nik Thread Applicator, HTI Plastics, Lincoln, 
NE); and nonlubricated male condoms (Alatech Health Care, Dothan, AL and Protector 
Plus, Surtex Limited, Thailand; distributed by Population Services International in 
Madagascar).
Acidform
Acidform gel has acidifying, bioadhesive, and viscosity-retaining properties intended to 
serve 2 purposes: to provide effective acidification of male ejaculate in the vagina, and to 
form a long-lasting layer of gel over the vaginal and cervical surfaces. Acid-form is buffered 
at pH 3.5, thus maintaining an acidic pH in the vagina after semen deposition. In addition, 
the gel bioadheres to form a protective layer with prolonged retention in the vagina.32,33 
Acidform shows antimicrobial activity against herpes simplex virus type 2, CT, GC, 
Trichomonas vaginalis and microbes leading to bacterial vaginosis.33–35 Phase I human 
safety trials and small-scale pilot studies indicate that Acidform is safe, well tolerated, and 
generally acceptable to women and men.36–42
HEC (Placebo Gel)
HEC is a safe, water-based gel formulation designed to be an inert control gel for masked 
trials of vaginal microbicides.43–45 The pH of HEC gel is 4.4.
All-Flex Arcing Spring Diaphragm
The All-Flex Arcing Spring Diaphragm is a molded, natural rubber vaginal diaphragm, 
approved by the US Food and Drug Administration for contraception when used with 
spermicide.
Study Procedures
At screening, women underwent testing for pregnancy and urinary tract infection (UTI) 
(Clearview HCG Combo, Wampole Laboratories, Cranbury, NJ and Multistix 10SG; Bayer, 
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Tarry-town, NY) and face-to face eligibility evaluation using a brief questionnaire. Eligible 
women were randomized to 4 groups: Acidform with diaphragm; HEC with diaphragm; 
HEC alone; and Acidform alone. Each woman was also randomly assigned a disposable 
paper or reusable plastic applicator; after 2 weeks, women switched applicator type for the 
second half of the study. Randomization was stratified by site. Treatment assignments were 
partially masked. Because of the nature of the intervention, assignment of diaphragms was 
not masked. However, neither participants, the on-site research staff, nor data analysts were 
aware of gel assignments.
At enrollment, 1 week after screening, participants received clinician-administered face-to-
face interviews to collect demographic, reproductive, and sexual behavior data. Clinicians 
also performed pregnancy testing for all women and diaphragm fitting for women 
randomized to the gel-diaphragm arms. All participants received counseling on use of their 
assigned study products, including male condoms, as well as sufficient supplies to last until 
the next study visit. All women received presumptive treatment for gonococcal, chlamydial, 
and trichomonal infections according to Madagascar’s national guidelines.3
Participants were instructed to use male condoms with every sex act. Women in the gel-
diaphragm arms were asked to use the diaphragm continuously, removing it once per 24-
hour period for cleaning. After cleaning, we requested that they fill the diaphragm dome 
with their assigned gel, using an applicator to ensure consistency in dose, and then reinsert 
the diaphragm. Participants in gel-only arms were instructed to insert their assigned gel 
intravaginally, again using an applicator, before each sex act. All women were instructed not 
to practice internal vaginal cleaning while participating in the study.
Participants returned once weekly for 4 weeks. At each visit, they again received face-to-
face interviews about their use of and problems with study products. Participants also 
underwent pelvic examination and received resupplies of study products. At the final follow-
up visit, women returned their diaphragms, applicators, and any unused gel.
Ethical Approval
All women gave written informed consent for screening and again for enrollment. The study 
was approved by institutional review boards at the University of North Carolina at Chapel 
Hill and the US Centers for Disease Control and Prevention (CDC), as well as the Comité 
d’Ethique auprès du Ministere de la Santé in Madagascar.
Young women aged 16 and 17 participated in this pilot trial. As with our other research in 
this population, we petitioned each of the 3 ethical review boards and were approved to 
classify adolescents as young as 15 years old as adults for the purposes of this study. The 
rationale for this classification was 2-fold. First, the highest STI morbidity among attendees 
of our clinics in Madagascar is seen among the youngest women,46 making these 
participants the very group most likely to benefit from the proposed research. Second, 
parental permission for participation was not feasible. Many adolescents receiving care in 
study clinics have run away from home and are living on their own or residing with a 
boyfriend. Most have no contact with a parent or guardian.
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Data from questionnaires and clinical examination were double entered in EpiInfo (Version 
6, CDC, Atlanta, GA) by staff at the data management unit LARTIC at the Université 
d’Antananarivo in Antananarivo, Madagascar and were verified at CDC. All analyses were 
conducted using SAS (SAS Institute, Version 9.1.3, Cary, NC).
Outcome measures—acceptability and feasibility—are summaries of several constructs. We 
evaluated participants’ comfort with products and recommended protocols for using them, 
including their patterns of use of gel with diaphragm and gel alone, and their reported ease 
of insertion, removal and cleaning of diaphragms and applicators; we assessed these 
behaviors by study arm and visit. We also examined the occurrence of self-reported 
genitourinary symptoms (itching, discharge, bleeding, pain, or problems urinating), 
clinician-identified abnormalities on pelvic examination, and adverse events (AEs) in each 
randomization group.
We assessed self-reported use of (a) condoms and (b) assigned experimental products by 
computing the proportion of sex acts with casual partners during which products were used. 
Using the total number of acts with casual partners as the offset variable, we fit separate 
unadjusted negative binomial regression models with robust variance estimators to generate 
the proportion and 95% confidence intervals (CIs) of sex acts with casual partners where 
condoms and experimental study products were used over the last week, by randomization 
group and follow-up visit. We used negative binomial regression rather than Poisson 
regression because of substantial extra-Poisson variability in some models. Because of the 
small number of women reporting primary partners and the low reported frequency of sex 
with those partners, and because sexual behavior is expected to differ depending on partner 
type, we restricted our measures of condom use and experimental product use to sex acts 
with casual partners.
We used intent-to-treat analysis guidelines47 and included all person-time contributed by all 
participants in the presented analyses. Because of the small sample size and the exploratory, 
descriptive purpose of this pilot study, we did not conduct formal statistical significance 
testing.
Results
The study was conducted between September and November 2005 and enrolled a total of 
192 women from the 4 clinical sites: 48 women per site and 48 women per randomization 
group.
Screening
Of 314 screened women, 192 (61%) were enrolled. The most common reasons for 
ineligibility were using condoms consistently in the past 2 weeks (37%), having fewer than 
4 partners in the past month (25%), planned or existing pregnancy (15%), and self-reported 
allergy to latex (11%).
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We saw few differences in baseline participant characteristics between randomization groups 
(Table 1). Few participants (11%) were married or cohabitating. In response to the question, 
“what kind of work do you do to earn money?” 81% reported sex work; when directly asked, 
100% reported that they had ever had sex to earn money. Age (median: 29 years), age at 
coital debut (median: 17 years), and completed years of education (median: 5.5 years) were 
similar across groups. More than half of participants (59%) had electricity in their homes, 
but running water was less common (18%). A majority (55%) had ever used highly effective 
contraception (hormonal methods, IUD, or sterilization), but use of these methods at the last 
sex act was lower (24%). Women frequently engaged in extensive vaginal hygiene practices 
(88% reported cleaning internally more than once daily).
Reported condom use was much higher with casual partners than with primary partners 
(husbands or boyfriends). Despite the exclusion at screening of women reporting consistent 
condom use with all partners, 48% of enrolled women reported always or almost always 
using condoms with casual partners compared with 11% with primary partners. More than 
half (55%) self-reported a previous STI or genital ulcer. The number of casual partners in a 
typical week [median: 6 partners, interquartile range (IQR): 4–9 partners], total sex acts in a 
typical week (median: 10 acts, IQR: 6–15 acts), and sex acts with the primary partner in the 
last week [among the subgroup of participants reporting a husband or boyfriend (n = 79, 
median: 2 acts, IQR: 1–3 acts)] were also similar across randomization groups (Table 1).
Follow-Up
Retention over the 4-week study period was 98% (188 participants attended the week 4 
visit). One participant voluntarily withdrew from the study, 1 woman was lost to follow-up, 
and 2 women were discontinued by study staff during follow-up because they were unable to 
insert the diaphragm. (All 4 participants had been randomized to the Acidform-diaphragm 
arm.)
Our analyses include 753 person-weeks (PW) of follow-up time: 178, 192, 192, and 191 
PWs from the Acidform-diaphragm, HEC-diaphragm, HEC-alone, and Acidform-alone 
arms, respectively.
Sexual Behavior
The median number of weekly sex acts with all partners, as well as the median number of 
casual partners, was higher during follow-up than at baseline for all randomization groups, 
though these figures are not strictly comparable because the baseline questionnaire asked 
about behavior during a typical week and the follow-up questionnaire asked about behavior 
in the past week. At enrollment, women’s median number of sex acts with all partners in a 
typical week was 10, 9, 8.5, and 10 acts for women in the Acidform-diaphragm, HEC-
diaphragm, HEC-alone, and Acid-form-alone arms, respectively. Over follow-up, the median 
sex acts with all partners in the past week were 15, 14, 14, and 12 acts, respectively. 
Women’s reported numbers of casual partners were similarly higher at follow-up than 
baseline; 7, 5, 6, and 5 casual partners in a typical week were reported at baseline by women 
in the Acidform-diaphragm, HEC-diaphragm, HEC-alone, and Acid-form-alone arms, 
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respectively, compared with 15, 12, 12, and 11 casual partners in the last week on average 
over follow-up.
Condom Use
Over the full follow-up period, participants used condoms in 66% of sex acts with casual 
partners (95% CI: 63%–68%) (Fig. 1). On average, Acidform-diaphragm users used 
condoms in 62% of acts with casual partners (95% CI: 57%–67%), HEC-diaphragm users in 
67% of acts (95% CI: 62%–73%), HEC-alone users in 66% of acts (95% CI: 60%–73%), 
and Acidform-alone users in 67% of acts (95% CI: 61%–73%). Generally, condom use 
increased throughout the study period, with the exception of the Acidform-diaphragm arm, 
in which condom use declined somewhat between weeks 3 and 4 (Fig. 1).
The proportion of sex acts with casual partners in which neither male condoms nor 
experimental products were used was low for all study groups (4% of sex acts overall, 95% 
CI: 3%–5%).
Diaphragm and Gel Use During Sex
The proportion of sex acts with casual partners in which experimental study products were 
used (regardless of condom use) ranged over follow-up and by arm, from a minimum of 
66% (HEC-alone arm, week 2) to a maximum of 94% of sex acts (HEC-diaphragm arm, 
week 4) (Fig. 2). In general, women in the 2 gel-diaphragm arms used products with casual 
partners more consistently (in 88% of acts, 95% CI: 84%–92%) than women in the 2 gel-
only arms (in 78% of acts, 95% CI: 74%–81%).
A comparison of the 2 gel-diaphragm groups indicates that women assigned to the HEC-
diaphragm arm used their study products with casual partners more consistently at every 
time point than women in the Acidform-diaphragm arm. This difference is most extreme at 
the final visit, with women in the Acidform-diaphragm arm using products in 81% of sex 
acts with casual partners and women in the HEC-diaphragm arm at 94% of acts. Comparing 
the gel-only arms, those in the Acid-form-alone arm used their products more consistently 
than those in the HEC-alone arm at every time point. Again, the most extreme difference 
occurred at the week 4 visit, where women in the HEC-alone arm used gel in 78% of sex 
acts with casual partners and women in the Acidform-alone arm in 86% of acts.
The number of participants in each study group who reported using experimental study 
products in 100% of sex acts with casual partners over the full 4 weeks of follow-up was 
low: 28% of women randomized to the Acidform-diaphragm arm, 29% of HEC-diaphragm 
users, 6% HEC-alone users, and 10% of Acid-form-alone users.
Participant Experiences With Diaphragm
Women in the 2 gel-diaphragm arms reported at 92% of follow-up visits that they were 
somewhat comfortable or comfortable wearing their diaphragms continuously, and the 
proportion expressing comfort with continuous use increased over time from 88% at the first 
follow-up visit to 95% at the final visit (Table 2). However, at approximately 20% of these 
visits, women also reported inserting the diaphragm more than once daily during the 
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previous week (an indication that they had not followed the continuous use protocol). 
Women reported at few visits that they ever left their devices in longer than 24 hours in the 
past week (reported at 4% of visits by 11 participants). Removal of the diaphragm after 
every sex act, regardless of partner type, was also rarely reported (at 4% of visits by 13 
participants). Most women (at 91% of visits in the Acidform-diaphragm arm and 96% of 
visits in the HEC-diaphragm arm) also said they did not reinsert gel intravaginally after the 
diaphragm was in place (reinsertion was not recommended under the protocol). Nearly all 
participants found inserting and removing the diaphragm easy (at 97% and 96% of visits, 
respectively).
Participant Experiences With Gel
At approximately half of visits, gel-only users reported that they inserted gel before each sex 
act as instructed (Table 3). The protocol did not recommend removing gel, but at roughly 
one-third of visits, women in both gel-only groups reported that they removed the gel after 
every sex act (regardless of partner type). Most reported that partners did not ask about the 
amount of lubrication or discharge (64% of visits in the HEC-alone arm and 73% in the 
Acidform-alone arm). Almost all women were somewhat or very comfortable using the gel 
applicator, with no differences by applicator type (paper or plastic); the proportion 
expressing comfort with the applicator also increased with time from 90% at the first follow-
up visit to 97% at the final visit. We did not directly ask participants which applicator they 
preferred.
Problems With Study Products
Women reported problems with study products at 76 visits (10%) over the study period. Gel-
diaphragm users were most likely to report trouble keeping the diaphragm in continuously or 
to have problems with partners’ reactions to study product use (for example, partner 
discovery of products or insistence on product removal before sex) (Tables 2 and 3). In gel-
only arms, most problems related to finding the time, opportunity or privacy to insert gel; 
trouble using the applicator; or problems with partners (such as a partner discovering the gel 
or applicator, or requesting that the participant wash before sex due to excess wetness). 
Problems declined somewhat by the end of follow-up: 19 women (10%) reported problems 
with study products at the first follow-up visit, 24 women (13%) at the second visit, 19 
women (10%) at the third visit, and 14 women (7%) at the final visit (Tables 2 and 3).
Genitourinary Signs and Symptoms
Women using Acidform (with the diaphragm or alone) reported more gynecological 
symptoms, including itching, discharge, bleeding, pain, or problems urinating, compared 
with those using placebo gel. During examination of the external and internal genitalia, 
clinicians noted more abnormalities (such as ulcers, mucopurulent cervicitis, inflammation, 
or discharge) among women in the Acidform-alone arm (Tables 2 and 3).
Adverse Events
A total of 131 AEs were reported in 88 women over the follow-up period. Fifty-six women 
(29% of all participants) had 1 AE, 25 participants (13%) had 2 AEs, and 7 (4%) had 3 or 
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more AEs (Table 4). AEs were more common in women using Acidform (62% of all AEs) 
than in participants using HEC. Most events (84%) required no action regarding product use, 
although investigators recommended stopping product use in 15 women (who reported 21 
events). Of those 15, 9 restarted product use within 1 week of the AE diagnosis; the other 6 
never reinitiated product use (2 of these experienced AEs at the final visit, so reinitiation was 
not an option). Most AEs (n = 103, 79%) resolved without sequellae, but a substantial 
minority (n = 23, 18%) remained unresolved at study exit. Information on resolution was 
missing for 5 AEs.
For all groups, the highest number of AEs was reported at the first follow-up visit. Most AEs 
(79%) were genitourinary (including cervical or vaginal discharge, irritation, frequent 
urination, reports of burning sensations or “local heat,” pelvic pain, or inflammation). 
Nongenitourinary AEs (21%) included headache, asthma, fever, influenza, and other 
respiratory and digestive infections. Three-quarters of AEs (n = 97, 74%) were possibly, 
probably or definitely related to use of study products; of these, the 3 events that were 
definitely related to product use occurred in women in the Acidform-diaphragm arm (2 
reports of temporary vaginal irritation and 1 report of pelvic pain). No serious AEs occurred.
No UTIs were detected during follow-up. A total of 3 pregnancies (1 in each of the 
Acidform-diaphragm, HEC-diaphragm, and HEC-alone arms) occurred. For the 1 pregnancy 
confirmed at the week 3 visit, product use was discontinued. The 2 other pregnancies were 
diagnosed at the last study visit, when products were removed from all participants.
Discussion
Our findings show that an intervention trial to assess the effectiveness of 2 woman-initiated 
methods of STI prevention will be both feasible and acceptable among high-risk women of 
low socioeconomic status whose main source of income is sex work. Women’s self-reported 
use of products during sex was high, and we saw no evidence of declining condom use (in 
fact, condom use increased between the first and final follow-up visits). Few women 
reported problems with their assigned products.
We enrolled 61% of screened women for this study, compared with 94% previously with this 
population using similar screening criteria.26 Recruitment took place during the Muslim 
holy month of Ramadan, when some women (particularly in Toamasina) in our target 
population abstained from sex and consequently failed to meet the inclusion criteria. 
Retention was very high.
Noncompliance with the recommended protocol was most pronounced among women in the 
2 gel-only arms, in which gel use was coitally-dependent: only half inserted gel before each 
sex act, and one-third removed the gel after each sex act. We hypothesize that an underlying 
issue affecting compliant vaginal gel use, particularly among the group that reported 
removing the gel after each act, is that many women engage in extensive internal vaginal 
hygiene practices.48 Exploration of participants’ genital hygiene practices and ramifications 
for adherent study product use, in particular gel use, was a secondary aim of this pilot trial, 
and a separate analysis on this topic is forthcoming. Following this pilot study, we convened 
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a workgroup including peer counselors, potential participants and clinicians to discuss new 
counseling strategies and modified vaginal hygiene practices that aim to optimize 
compliance with recommended protocols for product use for the RCT.
This pilot study was not powered to detect statistical differences between study groups for 
any outcome. However, we note that women in the 2 arms using active microbicide (with 
and without the diaphragm) had more self-reported gynecological symptoms and 
genitourinary AEs than women using placebo gel; women using the microbicide alone also 
had more clinician-noted abnormalities. Participants’ complaints (irritation, burning and 
itching) were similar to those described in previous safety studies of Acidform.38,39 As a 
result of these findings, we will replace Acid-form in the upcoming RCT with another 
candidate microbicide that has a similar acidifying mechanism of action, but with a superior 
safety profile. In addition, we will closely monitor safety related to product use among all 
participants. Sixty-four women will also be followed in an intensive safety substudy using 
colposcopy. This subset will be recruited for the coloscopy safety study at the start of the 
trial by inviting each newly enrolled participant to join, until 64 women have agreed to take 
part.
Two important findings from this formative work warrant additional attention. First, 
participants’ self-reported male condom use generally increased over the follow-up period. 
Free condom supplies and frequent counseling likely contributed to this increase, and it 
represents a positive health outcome. However, improved use of male condoms will likely 
also lower the expected STI incidence in the planned trial, potentially affecting power and 
precision. Lower-than-expected incidence, due in part to increased condom use, has been 
described in some HIV prevention studies.49,50 Second, self-reported weekly median 
number of sex partners and sex acts were higher during follow-up for every randomization 
group than had been reported at the baseline visit (although the enrollment questionnaire 
asked about the number of acts and partners in a typical week and follow-up questionnaires 
asked about the last week). Whether this finding represents true behavioral differences over 
time or simply reporting differences (for example, if participants intentionally underreported 
the number of partners or acts at enrollment because of social desirability concerns) is not 
known. Women completed a coital diary during follow-up; although diary data were not 
used for these analyses, perhaps making notes about their weekly behavior led to improved 
recall of sexual activity.
This study was designed to pilot-test several aspects of our proposed protocol to provide 
information about the best way to implement a large-scale RCT. It is limited by the small 
sample size and short follow-up time. In addition, a common limitation of research involving 
sexual behavior—assessing self-reported sensitive behavior through face-to-face interviews
—exists in this study, making these data subject to misreporting because of recall and social 
desirability biases. Also, because of the low number of women reporting a primary partner, 
and the low sexual frequency with primary partners among participants who had them, we 
were unable to examine product use with primary partners and therefore limited our 
modeling analyses to reported behavior during sex with casual partners. Finally, because of 
the study product characteristics, complete masking of randomization assignment was not 
possible.
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The recently published results of the MIRA trial showed no difference in HIV or STI risk 
between women assigned to use a diaphragm with a lubricant and male condoms, compared 
with women using condoms only.22,23 Of note, self-reported condom use was similar for 
both arms at baseline, but during follow-up, significantly more women in the diaphragm arm 
than in the control arm reported condom use during the last sex act.22 For the upcoming 
RCT, we are developing strategies to minimize possible product substitution by ensuring that 
participants understand the lack of evidence regarding the study products’ effectiveness.
In the MIRA trial, women were asked to insert the diaphragm before sex, whereas we 
instructed women to wear the diaphragm continuously. Throughout follow-up, 73% of the 
women in the MIRA diaphragm arm reported diaphragm use at last sex act. Noncoitally 
dependent diaphragm use could improve adherence. A second possible effect of continuous 
diaphragm use is that the device may remain in place longer after sex, providing more 
extended protection of vulnerable cervical tissue and possibly improving the effectiveness of 
the method against infection acquisition.
Unlike MIRA, our trial will evaluate the protective effect of the diaphragm plus candidate 
microbicide. Even if diaphragms alone do not provide protection against HIV, they may 
serve as effective vehicles for microbicide distribution,16 and our trial will answer this 
question with regard to STI outcomes.
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Proportion of sex acts with casual partners in the last week in which male condoms were 
used, with 95% confidence intervals, by randomization group and study visit.
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Proportion of sex acts with casual partners in the last week in which experimental study 
products were used (gel and diaphragm for gel-diaphragm groups and gel only for gel-only 
groups), with 95% confidence intervals, by randomization group and study visit.
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